Connecting Innovation to Purpose

Investment Summary Focus on developing precision oncology + differentiated assets Fi y Nectin-4 targeting ADC for treatment of solid tumors CB1R inverse agonist to treat obesity TGFB blocker Anti-avß8 integrin mAb for treatment of solid tumors CRBP Ticker $127 Million Cash investments as of Feb 2, 2024 and 10.3M Common Shares Outstanding (11.1M Fully-Diluted Shares)

View entire presentation